Is EQ or RLMD more profitable?

Equillium's return on equity of -61.43% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% Relmada Therapeutics N/A -71.22% -64.46%

Does the media prefer EQ or RLMD?

In the previous week, Equillium had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Equillium and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.94 beat Equillium's score of 0.06 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANRO or EQ more profitable?

Alto Neuroscience's return on equity of -47.22% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Equillium N/A -61.43% -53.72%

Is SLDB or EQ more profitable?

Equillium's return on equity of -61.43% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Equillium N/A -61.43% -53.72%

Does the media prefer SLDB or EQ?

In the previous week, Solid Biosciences had 7 more articles in the media than Equillium. MarketBeat recorded 14 mentions for Solid Biosciences and 7 mentions for Equillium. Solid Biosciences' average media sentiment score of 0.19 beat Equillium's score of 0.06 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ACRS or EQ?

In the previous week, Equillium had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Equillium and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.26 beat Equillium's score of 0.06 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to EQ or ZVRA?

In the previous week, Zevra Therapeutics had 14 more articles in the media than Equillium. MarketBeat recorded 21 mentions for Zevra Therapeutics and 7 mentions for Equillium. Zevra Therapeutics' average media sentiment score of 0.12 beat Equillium's score of 0.06 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Equillium (EQ) Competitors

$2.83 +0.16 (+6.03%)

Closing price 03:59 PM Eastern

Extended Trading

$2.84 +0.01 (+0.49%)

As of 07:39 PM Eastern

Compare

EQ vs. RLMD, ANRO, SLDB, ACRS, and ZVRA

Should you buy Equillium stock or one of its competitors? MarketBeat compares Equillium with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Equillium include Relmada Therapeutics (RLMD), Alto Neuroscience (ANRO), Solid Biosciences (SLDB), Aclaris Therapeutics (ACRS), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.

How does Equillium compare to Relmada Therapeutics?

Equillium (NASDAQ:EQ) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

In the previous week, Equillium had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Equillium and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.94 beat Equillium's score of 0.06 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.1% of Equillium shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 17.8% of Equillium shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Equillium has higher revenue and earnings than Relmada Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.36	-$22.40M	-$0.32	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Equillium has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Equillium presently has a consensus price target of $7.57, indicating a potential upside of 167.45%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 84.05%. Given Equillium's stronger consensus rating and higher probable upside, equities analysts plainly believe Equillium is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Equillium's return on equity of -61.43% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Equillium beats Relmada Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Equillium compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Alto Neuroscience currently has a consensus target price of $35.25, indicating a potential upside of 65.03%. Equillium has a consensus target price of $7.57, indicating a potential upside of 167.45%. Given Equillium's stronger consensus rating and higher possible upside, analysts plainly believe Equillium is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Equillium has higher revenue and earnings than Alto Neuroscience. Equillium is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Equillium	$41.10M	4.36	-$22.40M	-$0.32	N/A

Alto Neuroscience has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Alto Neuroscience's return on equity of -47.22% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Equillium	N/A	-61.43%	-53.72%

In the previous week, Equillium had 7 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Equillium and 0 mentions for Alto Neuroscience. Equillium's average media sentiment score of 0.06 beat Alto Neuroscience's score of 0.00 indicating that Equillium is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Equillium	Neutral

27.1% of Equillium shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Equillium beats Alto Neuroscience on 11 of the 14 factors compared between the two stocks.

How does Equillium compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Solid Biosciences had 7 more articles in the media than Equillium. MarketBeat recorded 14 mentions for Solid Biosciences and 7 mentions for Equillium. Solid Biosciences' average media sentiment score of 0.19 beat Equillium's score of 0.06 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium's return on equity of -61.43% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Equillium	N/A	-61.43%	-53.72%

Solid Biosciences presently has a consensus price target of $17.00, indicating a potential upside of 135.46%. Equillium has a consensus price target of $7.57, indicating a potential upside of 167.45%. Given Equillium's higher possible upside, analysts clearly believe Equillium is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Solid Biosciences has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Equillium has higher revenue and earnings than Solid Biosciences. Equillium is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Equillium	$41.10M	4.36	-$22.40M	-$0.32	N/A

Summary

Equillium beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does Equillium compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Equillium has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Aclaris Therapeutics currently has a consensus target price of $11.50, indicating a potential upside of 163.16%. Equillium has a consensus target price of $7.57, indicating a potential upside of 167.45%. Given Equillium's higher probable upside, analysts plainly believe Equillium is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Equillium had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Equillium and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.26 beat Equillium's score of 0.06 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Equillium	N/A	-61.43%	-53.72%

Equillium has higher revenue and earnings than Aclaris Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	77.95	-$64.92M	-$0.56	N/A
Equillium	$41.10M	4.36	-$22.40M	-$0.32	N/A

Summary

Equillium beats Aclaris Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Equillium compare to Zevra Therapeutics?

Equillium (NASDAQ:EQ) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

27.1% of Equillium shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 167.45%. Zevra Therapeutics has a consensus target price of $29.29, indicating a potential upside of 125.80%. Given Equillium's higher probable upside, research analysts clearly believe Equillium is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Equillium has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.36	-$22.40M	-$0.32	N/A
Zevra Therapeutics	$106.47M	7.20	$83.23M	$1.99	6.52

In the previous week, Zevra Therapeutics had 14 more articles in the media than Equillium. MarketBeat recorded 21 mentions for Zevra Therapeutics and 7 mentions for Equillium. Zevra Therapeutics' average media sentiment score of 0.12 beat Equillium's score of 0.06 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has a net margin of 101.58% compared to Equillium's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Zevra Therapeutics	101.58%	51.49%	28.86%

Summary

Zevra Therapeutics beats Equillium on 12 of the 16 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EQ vs. The Competition

Export

Metric	Equillium	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$168.82M	$3.38B	$6.51B	$11.99B
Dividend Yield	N/A	2.33%	2.67%	5.62%
P/E Ratio	N/A	19.79	24.24	24.11
Price / Sales	4.36	172.08	473.84	84.01
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	6.02	8.21	10.49	6.82
Net Income	-$22.40M	$23.89M	$3.56B	$337.52M
7 Day Performance	-10.69%	-3.00%	-2.02%	-0.96%
1 Month Performance	25.82%	-1.64%	0.66%	1.68%
1 Year Performance	633.42%	40.20%	21.85%	26.88%

Equillium Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EQ Equillium	2.7681 of 5 stars	$2.83 +6.0%	$7.57 +167.4%	+661.6%	$168.82M	$41.10M	N/A	40	Gap Up
RLMD Relmada Therapeutics	2.3387 of 5 stars	$6.42 -6.3%	$12.00 +86.9%	+705.4%	$673.39M	N/A	N/A	10
ANRO Alto Neuroscience	1.8765 of 5 stars	$18.76 -5.3%	$35.25 +87.9%	+648.7%	$658.22M	N/A	N/A	N/A
SLDB Solid Biosciences	2.5885 of 5 stars	$6.58 -8.5%	$16.36 +148.7%	+36.9%	$647.80M	N/A	N/A	100
ACRS Aclaris Therapeutics	3.1698 of 5 stars	$4.63 +6.7%	$11.50 +148.4%	+171.5%	$646.64M	$8.37M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EQ) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equillium (EQ) Competitors

EQ vs. RLMD, ANRO, SLDB, ACRS, and ZVRA

How does Equillium compare to Relmada Therapeutics?

Summary

How does Equillium compare to Alto Neuroscience?

Summary

How does Equillium compare to Solid Biosciences?

Summary

How does Equillium compare to Aclaris Therapeutics?

Summary

How does Equillium compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Equillium (EQ) Competitors

EQ vs. RLMD, ANRO, SLDB, ACRS, and ZVRA

How does Equillium compare to Relmada Therapeutics?

Does the media prefer EQ or RLMD?

Do insiders & institutionals have more ownership in EQ or RLMD?

Which has higher earnings and valuation, EQ or RLMD?

Which has more risk and volatility, EQ or RLMD?

Do analysts recommend EQ or RLMD?

Is EQ or RLMD more profitable?

Summary

How does Equillium compare to Alto Neuroscience?

Do analysts recommend ANRO or EQ?

Which has preferable valuation and earnings, ANRO or EQ?

Which has more volatility and risk, ANRO or EQ?

Is ANRO or EQ more profitable?

Does the media prefer ANRO or EQ?

Do institutionals and insiders have more ownership in ANRO or EQ?

Summary

How does Equillium compare to Solid Biosciences?

Does the media prefer SLDB or EQ?

Is SLDB or EQ more profitable?

Do analysts recommend SLDB or EQ?

Do institutionals & insiders have more ownership in SLDB or EQ?

Which has more risk & volatility, SLDB or EQ?

Which has stronger earnings & valuation, SLDB or EQ?

Summary

How does Equillium compare to Aclaris Therapeutics?

Which has more risk and volatility, ACRS or EQ?

Do analysts recommend ACRS or EQ?

Do insiders & institutionals have more ownership in ACRS or EQ?

Does the media favor ACRS or EQ?

Is ACRS or EQ more profitable?

Which has better valuation & earnings, ACRS or EQ?

Summary

How does Equillium compare to Zevra Therapeutics?

Do insiders and institutionals believe in EQ or ZVRA?

Do analysts recommend EQ or ZVRA?

Which has more risk & volatility, EQ or ZVRA?

Which has stronger earnings and valuation, EQ or ZVRA?

Does the media refer more to EQ or ZVRA?

Is EQ or ZVRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools